COVID-19 Clearinghouse
This page will house centralized content on COVID-19. Our aim is to make this page accessible and easy to navigate all the different resources on COVID-19 research, clinical trials, literature, reviews, etc. Specifically, we are focusing our interests on antiviral therapies. We are continuing to provide up-to-date information on ongoing trials, resources, treatments, and information regarding COVID-19.
We hope to make this site as up-to-date and interactive as possible. If you have information regarding current or previous clinical trials involving anti-viral treatments and COVID-19, please share it with us.
Disclaimer: This online resource does not provide medical advice and is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. This information should never replace professional medical advice or replace seeking treatment with a certified care provider.
Last Updated: May 25, 2020
Remdesivir
Drug Description
Monophosphoramidate prodrug (Yethindra 2020) |
Inhibits CoVs at early stages in replication by inhibiting viral RNA synthesis (Yethindra 2020) |
In mouse, prophylactic treatment and therapeutic treatment with GS-5734 decreased viral lung titers improved pulmonary function and symptoms in SARS-CoV (Sheahan et al 2017) |
Treating in elevating concentrations of GS-5734 may reduce levels of viral RNA associated with reduction of titer (Sheahan et al 2017) |
Broad spectrum antiviral nucleotide prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola Virus (Sheahan et al 2020)
|
Clinical Trials
Name of Study | Intervention | Location | Description | Progress |
Adaptive COVID-19 Treatment Trial
|
Remdesivir | Several sites throughout the United States, Republic of Korea, and Singapore | The study is a multicenter trial that will be conducted in up to 50 sites globally. The study will be a series of 2-arm comparisons between different investigational therapeutic agents and a placebo. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, this treatment will then become the control arm for comparison(s) with new experimental treatment(s). | Start Date: February 21, 2020 |
Antiviral Therapy and Baricitinib for the Treatment of Patients with Moderate or Severe COVID-19
|
Remdesivir Baricitinib Hydroxychloroquine Lopinavir/Ritonavir |
Los Angeles County-USC Medical Center USC / Norris Comprehensive Cancer Center Los Angeles, California, United States |
This phase II trial studies how well antiviral therapy works when given in combination with baricitinib for the treatment of moderate or severe coronavirus disease-2019 (COVID-19). Antiviral therapy such as hydroxychloroquine, lopinavir/ritonavir, and remdesivir may act against infections caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation and help prevent the need for being placed on a ventilator should the disease worsen. Giving antiviral therapy in combination with baricitinib may reduce the risk of the disease from getting worse compared to antiviral therapy alone. | Start Date: April 24, 2020 |
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. | TCM prescriptions antiviral drugs (i.e. IFN-α lopinavir/ritonavir, Ribavirin, Chloroquine Phosphate, Arbidol) |
Jiangsu Famous Medical Technology Co., Ltd. | This prospective multicenter cohort study observes the efficacy and safety of routine treatment + one or two of the following antiviral drugs + the following traditional Chinese medicine (TCM) regimens. | Start Date: March 2, 2020 |
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
|
Hydrosychloroquine Lopinavir/Ritonavir Pill Azithromycin Standard treatment |
Multiple Locations in Bogota, Columbia | Start Date: May 11, 2020 | |
Expanded Access Remdesivir (RDV; GS-5734™) | Remdesivir | The treatment of communicable Novel Coronavirus (CODIV-19) of 2019 with Remdesivir (RDV; GS-5734™) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | ||
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection | Remdesivir | Gilead Sciences | The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection. | Start Date: April 2020 |
|
Remdesivir Standard of care Lopinavir/ritonavir Interferon Beta-1A |
Institut National de la Santé Et de la Recherche Médicale, France |
The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19, the primary endpoint is the subject clinical status (on a 7-point ordinal scale) at day 15. | Start Date: March 2020 |
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections (REMDECO-19) | Remdesivir | Hôpital Cochin Paris, France, 75014 |
This study is a retrospective cohort trial to assess the efficacy of remdesivir in hospitalized adult patients diagnosed with COVID-19. The study is a multicenter trial which will be carried out on different sites in France. This trial is retrospective and will analyze the data collected during treatment. | Start Date: April 2020 |
Severe 2019-nCoV Remdesivir RCT
|
Remdesivir Remdesivir placebo |
Bin Cao Beijing Beijing, China |
Given the ready availability of remdesvir as a potential antiviral agent, based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with severe 2019-nCoV respiratory disease. | Start Date: February 6, 2020 |
|
Remdesivir vs. Standard of Care | Gilead Sciences (Stanford (CA) Newport Beach (CA) Seattle (WA) Everett (WA) Hong Kong South Korea Singapore Taiwan |
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19). | Start Date: March 15, 2020 |
|
Remdesivir vs. Standard of Care | Gilead Sciences (Stanford (CA) Newport Beach (CA) Seattle (WA) Everett (WA) Hong Kong South Korea Singapore Taiwan |
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19). | Start Date: March 6, 2020 |
The Efficacy of Different Anti-viral Drigs in COVID 19 Infected Patients
|
Remdesivir Hydroxychloroquine SoC |
Andreas Barratt-Due Oslo, Norway, 0756 |
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints. | Start Date: March 25, 2020 |
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
|
Lopinavir/Ritonavir | Sunnybrook Health Sciences Centre | This adaptive, randomized, open-label, controlled clinical trial evaluates the safety and efficacy of lopinavir/ritonavir combination treatment on COVID-19. | Start Date: March 18, 2020 |
Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)
|
Remdesivir Lopinavir/ritonavir Interferon Beta-1A Hydroxychloroquine Standard of care |
Institut National de la Santé Et de la Recherche Médicale, France |
The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. | Start Date: March 22, 2020 |
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study |
hydroxychloroquine
azithromycin remdesivir baricitinib tocilizumab sarilumab lopinavir/ritonavir oseltamivir |
Centre Hospitalier Intercommunal Robert Ballanger Aulnay-sous-Bois, France Centre Hospitalier Intercommunal Le Raincy-Montfermeil Montefermeil, France | Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, we retrospectively analyzed associations between specific treatments, including but not limited to hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation. | Start Date: March 14, 2020 |
Publications
Title | Authors | Journal | Date | PID | Summary |
Rapid review for the anti-coronavirus effect of remdesivir. | Ziyi Li, Xiaojie Wang, Donglin Cao, Ruilin Sun, Cheng Li, Guowei Li | Drug Discovery Therapy | 2020 | 32378648 | Summarizes the potential use of remdesivir in the treatment of COVID-19. Dicusses the safety of remdesivir in humans. |
Early Experience With Remdesivir in SARS-CoV-2 Pneumonia
|
Durante-Mangoni E., et al. | Infection | May 16, 2020 | 32418190 | We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19. |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial | Wang Y., et al. | The Lancet | April 29, 2020 | 32423584 | In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies. |
Remdesivir for the Treatment of Covid-19 — Preliminary Report | Beigel J. H., et al. | The New England Journal of Medicine | May 22, 2020 | We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. | |
Compassionate Use of Remdesivir for Patients With Severe Covid-19
|
Grein J, et al. | The New England Journal of Medicine | April 10, 2020 | 32275812 | In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). |
Lopinavir/Ritonavir
Drug Description
Clinical trails show no efficacy |
Protease inhibitor antiviral therapy (Sheahan et al 2020) |
anti-HIV drug combination of lopinavir and ritonavir - mainly targets protease during the process of producing new copies of HIV and coronavirus slash proteins using protease enzyme (Sheahan et al 2020) |
Human immunodeficiency virus (HIV-1) protease inhibitor that is usually combined with ritonavir (RTV) to increase lopinavir half-life through the inhibition of cytochrome P450 (Sheahan et al 2020) |
Binding analysis of the main SARS coronavirus proteinase with LPV showed that half of lopinavir is left outside of the catalytic site and the efficacy of lopinavir may be poor (Yao et al 2020)
|
Clinical Trials
Name of Study | Intervention | Location | Description | Progress |
Phase 4 |
Abidol hydrochloride Oseltamivir, Lopinavir/ritonavir |
Department and Institute of Infectious Disease Wuhan, Hubei, China |
In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. | Start Date: February 1, 2020 |
A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia | ASC09F+Oseltamivir Ritonavir+Oseltamivir Oseltamivir |
Department and Institute of Infectious Disease Wuhan, Hubei, China |
Based on oseltamivir treatment, evaluate the efficacy and safety of ASC09/ritonavir compound tablets(ASC09F) or ritonavir tablets for 2019-nCoV infection patients. | Start Date: February 1, 2020 |
Phase 4 |
Hydroxychloroquine Lopinavir / Ritonavir Interferon Beta-1A Interferon Beta-1B |
Shahid Beheshti University of Medical Sciences | The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. | Start Date: April 10, 2020 |
Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT) Phase 2,3 |
Chloroquine or Hydroxychloroquine Lopinavir/Ritonavir Rivaroxaban Thromboprophylaxis Candesartan non-RAS blocking antihypertensives Clazakizumab placebo |
Medical University of Vienna | The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19. | Start Date: April 16, 2020 |
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (COVIDAXIS) Phase 3 |
Hydroxychloroquine Placebo Lopinavir and ritonavir |
Centre Hospitalier Universitaire de Saint Etienne | The COVIDAXIS trial evaluates a chemoprophylaxis of SARS-CoV-2 infection in Health Care Workers. | Start Date: April 14, 2020 |
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. | TCM prescriptions antiviral drugs (i.e. IFN-α lopinavir/ritonavir, Ribavirin, Chloroquine Phosphate, Arbidol) |
Jiangsu Famous Medical Technology Co., Ltd. | This prospective multicenter cohort study observes the efficacy and safety of routine treatment + one or two of the following antiviral drugs + the following traditional Chinese medicine (TCM) regimens. | Start Date: March 2, 2020 |
Phase 2 |
Lopinavir/ritonavir hidroxicloroquine, imatinib tablets baricitinib oral tablet |
Hospital Universitario de Fuenlabrada | The study aims to compare lopinavir / ritonavir (200 /50), imatinib 400mg, baricitinib 4mg, in combination with hydroxychloroquine 200mg, administered for 7 days in the setting of SARS-CoV-2 pneumonia treatment. | Start Date: April 13, 2020 |
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection | Hyperimmune plasma Hidroxicloroquina + Azitromicina Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina |
Hospital Unversitario Virgen Macarena Sevilla, Spain |
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection. | Start Date: April 2020 |
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease Phase 2 |
Lopinavir/ritonavir Hydroxychloroquine sulfate |
Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea |
This study investigates whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimens in patients with mild COVID-19. | Start Date: March 11, 2020 |
Phase 2,3 |
lopinavir/ritonavir Hydroxychloroquine Sulfate Losartan Placebos |
Bassett Healthcare | This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo. | Start Date: April 6, 2020 |
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR) Phase 3 |
Lopinavir/Ritonavir | St. Michael's Hospital, Toronto | This is a cluster randomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that will address the immediate need for preventive interventions, generate key data on COVID-19 transmission, and serve as a research platform for future vaccines and preventive agents. | Start Date: March 30, 2020 |
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia | Hydroxychloroquine Lopinavir/Ritonavir Azithromycin SoC |
Multiple sites in Columbia | Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab). Clinical trials offer conflicting evidence regarding the effectiveness and safety of therapies The real effectiveness and safety profile of the treatments for COVID-19 remains unknown. | Start Date: May 11, 2020 |
Phase 4 |
Danoprevir+Ritonavir | Huoshenshan Hospital | Evaluation of the efficacy and safety of Danoprevir sodium tablet combined with ritonavir for SARS-CoV-2 infected patients. | Start Date: March 18, 2020 |
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland (COPEP) | Hydroxychloroquine Sulfate Lopinavir/ritonavir |
Universitätsspital Basel and SwissTPH Basel, Switzerland Hôpitaux Universitaires de Genève Geneva, Switzerland |
A study to assess, in a three-arm open-label cluster randomized clinical trial, the efficacy of a single-dose of HCQ treatment and of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient, compared to surveillance alone. | Start Date: April 2020 |
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection | ASC09/ritonavir lopinavir/ritonavir |
First Affiliated Hospital of Zhejiang University | Based on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia. | Start Date: February 7, 2020 |
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Phase 2,3 |
Levamisole Pill + Budesonide+Formoterol inhaler Lopinavir/Ritonavir + hydoxychloroquine |
Fasa University of Medical Sciences | This study evaluates the safety and efficacy a new strategy for treatment of COVID-19 which consists of local anti- inflammatory and systemic immune stimulant drugs. | Start Date: March 31, 2020 |
Phase 4 |
Ganovo + ritonavir +/-Interferon nebulization | The Ninth Hospital of Nanchang Nanchang, Jiangxi, China |
Given no specific antiviral therapies for new coronavirus pneumonia approved yet and Ganovo, an oral Hepatitis C virus protease inhibitor, approved in China in June 2018 , this open, controlled trial will evaluate the efficacy and safety of Ganovo in hospitalized patients infected with 2019-nCoV. | Start Date: February 17, 2020 |
Phase 4 |
Interferon Beta-1A Lopinavir/Ritonavir Single Dose of Hydroxychloroquine |
Shahid Beheshti University of Medical Sciences | The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. | Start Date: April 15, 2020 |
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Phase 2 |
Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B | University of Hong Kong Queen Mary Hospital Hong Kong, Hong Kong |
A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir | Start Date: February 10, 2020 |
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) | Lopinavir / ritonavir tablets Xiyanping injection |
Jiangxi Qingfeng Pharmaceutical Co. Ltd. | This study is a Randomized, Parallel Controlled Clinical Study to treat patients with COVID-19 infection to observe the efficacy and safety of liponavir/ritonavir antiviral treatment combined with Xiyanping injection. | Start Date: March 14, 2020 |
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (OUTCOV) | Azithromycin Hydroxychloroquine Lopinavir 200Mg/Ritonavir 50Mg |
Multiple sites in France | Our primary objective is to evaluate the efficacy of early outpatient treatment compared to standard of care in patients COVID-19 with risk factors for poor outcome. The criteria is hospital admission at Day 20 and the hospital admission rate will be compared between groups by a Chi² test or a Fisher's exact test. | Start Date: April 28, 2020 |
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 (PROTECT-Surg) Phase 3 |
Lopinavir-Ritonavir Hydroxychloroquine |
The aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs) | Start Date: May 15, 2020 | |
Randomized Evaluation of COVID-19 Therapy Phase 2,3 |
Lopinavir-Ritonavir Corticosteroid Hydroxychloroquine Azithromycin Tocilizumab |
Nuffield Department of Population Health, University of Oxford Oxford, United Kingdom | RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin or Tocilizumab prevents death in patients with COVID-19 | Start Date: March 19, 2020 |
The Clinical Study of Carrimycin on Treatment Patients With COVID-19 | Carrimycin lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate |
A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression. | Start Date: February 23, 2020 | |
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients Phase 2 |
Liponavir/Ritonavir hydroxychloroquine sulfate baricitinib sarilumab |
Nova Scotia Health Authority Halifax, Nova Scotia, Canada |
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment | Start Date: April 2020 |
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO) Phase 2 |
Lopinavir/Ritonavir | Sunnybrook Health Sciences Centre | This adaptive, randomized, open-label, controlled clinical trial evaluates the safety and efficacy of lopinavir/ritonavir combination treatment on COVID-19. | Start Date: March 18, 2020 |
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (TREAT NOW) Phase 2 |
Lopinavir/ritonavir hydroxychloroquine placebo |
University of Colorado School of Medicine Aurora, Colorado, United States Beth Israel Deaconess Medical Center Boston Massachusetts, United States Vanderbilt University Medical Center Nashville, Tennessee, United States |
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine vs lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19 | Start Date: May 1, 2020 |
Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy) Phase 4 |
Remdesivir Lopinavir/ritonavir Interferon Beta-1A Hydroxychloroquine Standard of care |
Institut National de la Santé Et de la Recherche Médicale, France | The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. | Start Date: March 22, 2020 |
Umifenovir in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (UAIIC) Phase 4 |
Umifenovir Interferon-β 1a Lopinavir / Ritonavir Single Dose of Hydroxychloroquine Standards of Care |
Shahid Beheshti University of Medical Sciences | The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. | Start Date: April 15, 2020 |
Phase 3 |
Oseltamivir Chloroquine Lopinavir Ritonavir Favipiravir Oseltamivir Darunavir |
Thailand, Rajavithi Hospital | A 6-Week Prospective, Open label, Randomized, in Multicenter Study evaluating the efficacy and safety of various combinations of protease inhibitors in the treatment of COVID-19. | Start Date: March 15, 2020 |
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia | Xiyanping injection Lopinavir/ritonavir alpha-interferon nebulization |
Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia. | Start Date: February 14, 2020 |
Publications
Title | Authors | Journal | Date | PID | Summary |
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | Bin Cao, M.D., Yeming Wang, M.D., Danning Wen, M.D., Wen Liu, M.S., et al. | The New England Journal of Medicine | May 7, 2020 | 32187464 | We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. |
Chloroquine/Hydroxychloroquine
Drug Description
Chloroquine
Known to suppress immune activation by a number of mechanisms, including inhibition of intracellular toll-like receptor (TLR) signaling and inflammatory cytokine secretion (Murray et al 2010) |
In vitro, shown to reduce HIV infection-induced T-cell immune activation (Murray et al 2010)
|
Antiretroviral effect on HIV-1 attributable to post-transcriptional inhibition of glycosylation of the gp120 envelope glycoprotein and neosynthesized virus particles are non-infectious (Devaux et al 2020) |
Hydroxychloroquine
Shown to have some efficacy in mild disease |
Less toxic than chloroquine |
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial |
Clinical Trials
Name of Study | Intervention | Location | Description | Progress |
A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) Phase 4 |
Hydrozychloroquine | Oregon Health and Science University Portland, Oregon, United States |
This is a prospective, randomized, participant-blinded, placebo-controlled, pilot study to assess the preliminary efficacy and safety of hydroxychloroquine for the treatment of patients with lower respiratory tract SARS-CoV-2 infection. | Start Date: May 2020 |
Phase 3 |
Hydroxychloroquine | Queen's Medical Centre | The overall objective is to evaluate the clinical efficacy and safety of hydroxychloroquine (HCQ) relative to standard of care among 350 hospitalized adult patients who have COVID-19. | Start Date: March 26, 2020 |
A Real-life Experience on Treatment of Patients With COVID 19 Phase 2,3 |
Chloroquine Favipiravir Nitazoxanide Ivermectin Niclosamide |
Tanta University | COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin. | April 15, 2020 |
Phase 2 |
Hydroxychloroquine Vitamin C Vitamin D Zinc |
ProgenaBiome | This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent infection with COVID-19 | Start Date: April 2020 |
A Study of Quintuple Therapy to Treat COVID-19 Infection (HAZDpaC) Phase 2 |
Hydroxychloroquine Azithromycin Vitamin C Vitamin D Zinc |
ProgenaBiome | This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection). | Start Date: April 2020 |
ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease Phase 3 |
Hydroxychloroquine | University of Calgary | This double-blind placebo-controlled, randomized clinical trial will determine if hydroxychloroquine for 5 days, initiated within 96 hours of confirmation of a positive COVID-19 result, and within 12 days of symptom onset, reduces the occurrence of severe COVID-19 disease. | Start Date: April 13, 2020 |
Phase 4 |
Hydroxychloroquine Lopinavir / Ritonavir Interferon Beta-1A Interferon Beta-1B |
Shahid Beheshti University of Medical Sciences | The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. | Start Date: April 10, 2020 |
Phase 3 |
Azithromycin Chloroquine |
Population Health Research Institute | ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19. | Start Date: April 1, 2020 |
Phase 4 |
Hydroxychloroquine Azithromycin |
Abderrahmane Mami Hospital | The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities | Start Date: April 15, 2020 |
Phase 3 |
Hydroxychloroquine | Abderrahmane Mami Hospital | Interventional, Multicentric, Randomized Controlled Study in Two Parallel Groups of 530 Healthcare Professionals working in the Intensive Care Unit Exposed to Risk of COVID19 Infection Taking Hydroxychloroquine (HCQ) (200 mg/day) VS Placebo | Start Date: Apri 15, 2020 |
Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT) Phase 2,3 |
Chloroquine or Hydroxychloroquine Lopinavir/Ritonavir Rivaroxaban Thromboprophylaxis Candesartan non-RAS blocking antihypertensives Clazakizumab |
Medical University of Vienna | The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19. | Start Date: April 16, 2020 |
Phase 3 |
Azithromycin Hydroxychloroquine Placebo |
Frantisek Duska Charles University Czech Republic |
A trial in which we test a hypothesis, that early administation of hydrochlorochine alone or in combination with azithromycin can prevent respiratory deterioration in patients admitted to intensive care due to rapidly progressive COVID-19 infection. | Start Date: April 20, 2020 |
Azithromycin in Hospitalized COVID-19 Patients Phase 4 |
Hydroxychloroquine Azithromycin |
Shahid Modarres Hospital Shahid Beheshti University of Medical Sciences and Health Services Tehran, Iran, Islamic Republic of |
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. | Start Date: April 20, 2020 |
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (COVIDAXIS) Phase 3 |
Hydroxychloroquine Lopinavir and ritonavir |
Centre Hospitalier Universitaire de Saint Etienne | The COVIDAXIS trial evaluates a chemoprophylaxis of SARS-CoV-2 infection in Health Care Workers. | Start Date: April 14, 2020 |
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID Phase 2 |
Chloroquine | Columbia University | The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. | April 2020 |
ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020 (QUARANTINE2020) Phase 4 |
Chloroquine phosphate Telemedicine |
Wroclaw Medical University | The aim of the study is to evaluate whether the therapy with chloroquine phosphate (CQ, in combination with telemedical approach) in addition to standard care is effective and safe in reducing composite endpoint of COVID-19-related hospitalization or all cause death. | Start Date: April 6, 2020 |
Phase 2 |
Chloroquine diphosphate | Fundação de Medicina Tropical | The investigators intend to investigate the efficacy and the safety of CQ diphosphate in the treatment of hospitalized patients with severe acute respiratory syndrome in the scenario of SARS-CoV2. | Start Date: March 23, 2020 |
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 Phase 2,3 |
Chloroquine standard care |
HaEmek Medical Center, Israel | The purpose of this study is to test whether a low dose of Chloroquine will reduce the duration of the viral shedding and prevent the disease from worsening. | Start Date: April 2020 |
Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 Phase 3 |
Chloroquine or hydroxychloroquine | Khayelitsha Hospital Groote Schuur Hospital Cape Town, Western Cape, South Africa |
The trial objective is to compare chloroquine (or hydroxychloroquine) versus standard of care for the primary endpoint of hospitalisation or death at 28 days. Consenting adults who meet criteria for a Covid-19 person under investigation and who are ≥18 years, known to be HIV-positive, not requiring immediate hospitalisation and are not at risk of cardiac toxicities related to the study drug will be enrolled. | Start Date: May 1, 2020 |
Phase 2 |
UNIKINON (Chloroquine phosphate) | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | The study aims to document possible prevention of pneumonia in patients staying at home and in improving the symptoms of SARS-CoV-2 pneumonia in patients who will be hospitalised. | Start Date: April 6, 2020 |
Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) | Chloroquine | University of Oxford | The study is a double-blind, randomised, placebo-controlled trial that evaluates the efficacy and safety of chloroquine in the treatment of coronavirus disease 2019. | Start Date: May 2020 |
Phase 4 |
Chloroquine Sulfate Hydroxychloroquine Standard supportive care |
UMCU Utrecht, Netherlands |
Multicentre, cluster randomized cross-over, open label trial. Hospitals will be randomly allocated to one of 3 treatment arms in sequential periods of one week: chloroquine base versus hydroxychloroquine versus supportive care without any drug presumed active against SARS-COV-2. Patients will be treated based on the date of inclusion. | Start Date: April 14, 2020 |
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) | Chloroquine Hydroxychloroquine |
University of Oxford | This study evaluates the safety and efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. | Start Date: April 2020 |
Phase 2 |
Tocilizumab Hydroxychloroquine Azithromycin |
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | This clinical trial is designed to evaluate the use of Tocilizumab in combination with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients with COVID-19. | Start Date: April 2, 2020 |
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. | TCM prescriptions antiviral drugs (i.e. IFN-α lopinavir/ritonavir, Ribavirin, Chloroquine Phosphate, Arbidol) |
Jiangsu Famous Medical Technology Co., Ltd. | This prospective multicenter cohort study observes the efficacy and safety of routine treatment + one or two of the following antiviral drugs + the following traditional Chinese medicine (TCM) regimens. | Start Date: March 2, 2020 |
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 (CLOCC) Phase 4 |
Camostat Mesilate Hydroxychloroquine |
Heinrich-Heine University, Duesseldorf | The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19. | Start Date: June 1, 2020 |
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease Phase 2 |
Lopinavir/ritonavir Hydroxychloroquine sulfate |
Asan Medical Center University of Ulsan College of Medicine Seoul, Korea |
This study investigates whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimens in patients with mild COVID-19. | Start Date: March 11, 2020 |
Phase 2,3 |
Plasma Hydroxychloroquine, Azithromycin |
Universidad del Rosario | The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). | Start Date: April 1, 2020 |
Phase 2,3 |
lopinavir/ritonavir Hydroxychloroquine Sulfate Losartan |
Bassett Healthcare | This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo. | Start Date: April 6, 2020 |
Phase 2 |
Chloroquine Hydroxychloroquine Placebo |
Washington University School of Medicine | The trial will evaluate which of the intervention arms is most effective at decreasing the incidence of severe COVID-19 disease, without unacceptable side effects or safety events. | Start Date: April 2020 |
Double Therapy With IFN-beta 1b and Hydroxychloroquine Phase 2 |
Interferon Beta-1B Hydroxychloroquine |
The University of Hong Kong | We propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and hydroxychloroquine combination treatment for patients hospitalized for COVID-19 infection. | Start Date: April 9, 2020 |
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
Phase 2,3
|
Hydroxychloroquine Lopinavir/Ritonavir Azithromycin SoC |
Multiple sites in Columbia | Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Chloroquine (CQ) and Hydroxychloroquine (HCQ), Lopinavir/Ritonavir (Lop/r), Remdesivir, Favipavir, acting over bacterial co-infection Azithromycin (Azithro), or modifying the inflammatory response of the host (Tocilizumab). Clinical trials offer conflicting evidence regarding the effectiveness and safety of therapies The real effectiveness and safety profile of the treatments for COVID-19 remains unknown. | Start Date: May 11, 2020 |
Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid) Phase 3 |
Hydroxychloroquine Azithromycin |
Ayub Medical College, Abbottabad | A single centered, single-blind randomized control trial study to find the effectiveness of hydroxychloroquine alone and adjuvant with azithromycin in mild to severe Covide-19 pneumonia patients. | Start Date: March 28, 2020 |
Phase 1 |
Hydroxychloroquine Sulfate Azithromycin |
Azidus Brasil | This is an exploratory, open label, multi-center study to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (AZT) to treat moderate to severe COVID-19 pneumonia. | Start Date: April 3, 2020 |
Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ) Phase 3 |
Hydroxychloroquine | Shanghai Public Health Clinical Center Shanghai, China |
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of pneumonia caused by the 2019 novel coronavirus. | Start Date: February 6, 2020 |
Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19 Phase 4 |
Hydroxychloroquine Sulfate 200 MG | Taoyuan General Hospital, Ministry of Health and Welfare Taoyuan City, Taiwan | This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to moderate coronavirus disease (COVID-19) compared to standard of care treatment (SOC). | Start Date: April 1, 2020 |
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients (MG-COVID)
Phase 3
|
Hydroxychloroquine and Azithromycin Azinc |
The main objective is to assess the efficacy of Hydroxychloroquine combined with azithromycin in COVID-19 patients in primary care, in add-on to standard of care, on unfavorable outcome defined by the onset of at least one of the following between D0 and D14: hospitalization, death or percutaneous O² saturation ≤ 92% in ambient air. | Start Date: May 1, 2020 | |
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland (COPEP)
|
Hydroxychloroquine Sulfate Lopinavir/ritonavir |
Universitätsspital Basel and SwissTPH Basel, Switzerland Hôpitaux Universitaires de Genève Geneva, Switzerland |
A study to assess, in a three-arm open-label cluster randomized clinical trial, the efficacy of a single-dose of HCQ treatment and of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient, compared to surveillance alone. | Start Date: April 2020 |
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Phase 2,3 |
Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine | Fasa University of Medical Sciences | This study evaluates the safety and efficacy a new strategy for treatment of COVID-19 which consists of local anti- inflammatory and systemic immune stimulant drugs. | Start Date: March 31, 2020 |
Phase 3 |
Hydroxychloroquine and azithromycin Hydroxychloroquine |
This study wants to evaluate the clinical impact of adding Azithromycin to Hydroxychloroquine in the treatment of Sars-CoV-2 pneumonia | Start Date: May 1, 2020 | |
Favipiravir in Hospitalized COVID-19 Patients (FIC)
Phase 4
|
Favipiravir Hydroxychloroquine |
Shahid Modarres Hospital Shahid Beheshti University of Medical Sciences and Health Services Tehran, Iran, Islamic Republic of |
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. | Start Date: April 20, 2020 |
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers Phase 3 |
Hydroxychloroquine | Medical University of Vienna | To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo controlled, study. | Start Date: April 2020 |
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ) Phase 3 |
Hydroxychloroquine | Duke University | This is a double blind, placebo controlled study in approximately 15,000 health care workers at risk for being exposed to COVID-19 to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19. | Start Date: April 2020 |
High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 Phase 1 |
Hydroxychloroquine | University of Chicago | Our hypothesis is that targeting high risk patients earlier in the disease course and with a higher dose regimen are both required to see improvement in disease outcome measures in COVID-19. This study aims to prove the tolerability of high dose HCQ in this setting. | Start Date: April 2020 |
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers Phase 2 |
Hydroxychloroquine Sulfate (HCQ) | Hackensack Meridian Health | The study proposes to conduct an open-label Phase II trial to evaluate the feasibility, safety and early efficacy of hydroxychloroquine (HCQ) administration in reduction of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and development of Corona Virus Disease 2019 (COVID-19) in high-risk, healthy acute care provider participants exposed, directly or indirectly, to COVID-19 patients. | Start Date: April 14, 2020 |
Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) Phase 3 |
Hydroxychloroquine | Gangnam Severance Hospital | In this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. | Start Date: April 1, 2020 |
Phase 3 |
Hydroxychloroquine | National Institute of Respiratory Diseases, Mexico | Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients. | Start Date: April 1, 2020 |
Hydroxychloroquine for COVID-19 (COV-HCQ) Phase 3 |
Hydroxychloroquine Sulfate | University Hospital Tuebingen | We propose to conduct a placebo-controlled trial in COVID-19 patients with mild to moderate disease in Germany to assess virological efficacy, tolerability and safety of hydroxychloroquine in the treatment of COVID-19. | Start Date: March 29, 2020 |
Hydroxychloroquine for COVID-19 PEP Phase 1 |
Hydroxychloroquine Sulfate Ascorbic Acid |
University of Washington | This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of Hydroxychloroquine (HCQ) post-exposure prophylaxis (PEP) for the prevention of SARS-CoV-2 infection in adults exposed to the virus. | Start Date: March 2020 |
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease Phase 3 |
Hydroxychloroquine | University Hospital Tuebingen | The aim of this placebo-controlled trial is to assess the effect of hydroxychloroquine on duration of symptoms in mild COVID-19 patients and time of virus shedding as an important tool to reduce the risk of further community transmissions. | Start Date: April 10, 2020 |
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease (COMIHY) Phase 3 |
Hydroxychloroquine | University Hospital Tuebingen | The aim of this placebo-controlled trial is to assess the effect of hydroxychloroquine on duration of symptoms in mild COVID-19 patients and time of virus shedding as an important tool to reduce the risk of further community transmissions. | Start Date: April 10, 2020 |
Phase 1 |
Hydroxychloroquine | Rambam Health Care Campus | The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. | Start Date: March 2020 |
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients | HCQ & AZ vs HCQ+SIR | King Hussein Cancer Center Amman, Jordan |
The evidence for using sirolimus for influenza is emphasized by a RCT that showed reduction of mechanical ventilation time by 50% (7 days on sirolimus arm vs 15 days on oseltamivir/steroids arm). Safe administration in human subjects is illustrated by multiple phase I/II clinical trials, performed in patients with cancer. COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B). | Start Date: May 1, 2020 |
Hydroxychloroquine in Outpatient Adults With COVID-19 Phase 1 |
Hydroxychloroquine SAR321068 | Sanofi | To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 | Start Date: March 31, 2020 |
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4 |
Hydroxychloroquine Vitamin C |
Providence Health & Services | This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19. | Start Date: March 30, 2020 |
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers Phase 2 |
Hydroxychloroquine | Baylor Research Institute | This study assesses the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection. | Start Date: April 3, 2020 |
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) Phase 2,3 |
Hydroxychloroquine | Columbia University | The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients. | Start Date: March 2020 |
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA) Phase 3 |
Hydroxychloroquine | National Institute of Respiratory Diseases, Mexico | Double blinded randomized clinical trial designed to evaluate the security and efficacy of hydroxychloroquine as treatment for COVID-19 severe respiratory disease. | Start Date: March 23, 2020 |
Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore Phase 2 |
Hydroxychloroquine | Montefiore Medical Center | Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Montefiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness. | Start Date: April 2020 |
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease (HYCOVID) Phase 3 |
Hydroxychloroquine | University Hospital, Angers | The research hypothesis is that treatment with hydroxychloroquine improves prognosis and reduces the risk of death or use for invasive ventilation in patients with COVID-19. | Start Date: April 2020 |
Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19 Phase 4 |
Nitazoxanide Hydroxychloroquine |
Materno-Perinatal Hospital of the State of Mexico | The purpose of this study is to contrast the beneficial effect of NTZx vs NTZx plus hydroxychloroquine in patients Coronavirus Disease (COVID-19) as well as against other treatments. | Start Date: April 6, 2020 |
Phase 2 |
Hydroxychloroquine Azithromycin |
University of Utah | This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19. | Start Date: March 30, 2020 |
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT) Phase 3 |
Hydroxychloroquine Azithromycin |
University of Utah Utah Department of Health |
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating outpatients with suspected or confirmed COVID-19. | Start Date: April 2, 2020 |
Hydroxychloroquine, Hydroxychloroquine, Azithromycin in the Treatment of SARS CoV-2 Infection (WU352) | Hydroxychloroquine Sulfate Azithromycin Chloroquine Sulfate |
Washington University School of Medicine | This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection. | Start Date: April 4, 2020 |
Phase 3 |
Hydroxychloroquine Oseltamivir Azithromycin |
University of Health Sciences Lahore | To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate vs oseltamivir vs Azithromycin in the treatment of COVID-19. | Start Date: April 7, 2020 |
Phase 3 |
Hydroxychloroquine | Universidad Nacional de Colombia | This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). | Start Date: April 20, 2020 |
Phase 4 |
Interferon Beta-1A Lopinavir/Ritonavir Single Dose of Hydroxychloroquine |
Shahid Beheshti University of Medical Sciences | The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. | Start Date: April 15, 2020 |
Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients Phase 1 |
Ivermectine Hydroxychloroquine Sulfate Placebos |
University of Baghdad | Comparing the efficacy and safety of adjuvant use of Ivermectin in covid19 patients with pneumonia using Ivermectin with hydroxychloroquine compared to HCQ | Start Date: April 8, 2020 |
Early Phase 1 |
Hydroxychloroquine Sulfate Bromhexine |
Instituto Nacional de Rehabilitacion | This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City. | Start Date: April 10, 2020 |
Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study Phase 2 |
Hydroxychloroquine | United States Department of Defense | A well-designed study to evaluate whether there is value in using Hydroxychloroquine or Chloroquine as a pre-exposure prophylaxis or post-exposure prophylaxis regimen for COVID-19 patients and at risk personnel. | Start Date: April 2020 |
Norwegian Coronavirus Disease 2019 Study Phase 4 |
Hydroxychloroquine Sulfate | University Hospital, Akershus | Aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine. | Start Date: March 23, 2020 |
Phase 3 |
Hydroxychloroquine | Massachusetts General Hospital | ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. | Start Date: April 2, 2020 |
Phase 2 |
Hydroxychloroquine Azithromycin |
Duke University | This is a phase II, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two potential treatments for hospitalized patients with confirmed SARS-CoV-2 infection. | Start Date: April 2020 |
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds (PEACE)
Phase 4
|
Hydroxychloroquine Sulfate Chloroquine Placebo |
Expo Covid Center Mayo Hospital Pakistan Kidney and Liver Institute Lahore, Punjab, Pakistan |
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients. | Start Date: April 14, 2020 |
Post-exposure Prophylaxis for SARS-Coronavirus-2 Phase 3 |
Hydroxychloroquine | University of Minnesota Minneapolis, Minnesota, United States | Chloroquine or Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID19 disease or early preemptive therapy may ameliorate disease severity. This trial will use a modification of standard malaria dosing of hydroxychloroquine to provide post-exposure prophylaxis / preemptive therapy. | Start Date: March 17, 2020 |
Phase 3 |
Hydroxychloroquine | Barcelona Institute for Global Health | The investigators aim to evaluate the efficacy of pre-exposure prophylaxis with hydroxychloroquine in healthcare workers with high-risk of SARS-CoV-2 infection. | Start Date: April 3, 2020 |
Preventing COVID-19 in Healthcare Workers With HCQ: A RCT Phase 2 |
Hydroxychloroquine Vitamin C |
Stony Brook University | Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to hydroxychloroquine or Vitamin C on a weekly basis for three months. | Start Date: April 20, 2020 |
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 (PROTECT-Surg)
Phase 3
|
Lopinavir-Ritonavir Hydroxychloroquine |
The aim of this study is to reduce COVID-19 related pulmonary complications in adult patients undergoing all types of elective or emergency surgery in a COVID-19 exposed environment. A Trial in Low and Middle Income Countries (LMICs) and A Trial in High Income Countries (HICs) | Start Date: May 15, 2020 | |
Phase 2 |
Azithromycin Hydroxychloroquine Placebo oral tablet |
Chronic Obstructive Pulmonary Disease Trial Network, Denmark | This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during hospitalization. | Start Date: April 6, 2020 |
Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia | Plaquenil 200Mg Tablet | Istinye University | Main purpose of the study was to cover participants those who are facing or treating COVID19 infected patients in Ankara. | Start Date: March 20, 2020 |
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds Phase 4 |
Hydroxychloroquine Chloroquine Placebo |
Expo Covid Isolation Center / Mayo Hospital Field Hospital Mayo Hospital / King Edward Medical University Pakistan Kidney and Liver Institute Services Hospital Lahore, Punjab, Pakistan |
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection. | Start Date: Apri 15, 2020 |
Qatar Prospective RCT Of Therapy Eliminating Covid Transmission (Q-PROTECT) | Hydroxychloroquine Azithromycin Placebo |
Hamad Medical Corporation | Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19. | Start Date: April 14, 2020 |
Phase 3 |
Emtricitabine/tenofovir disoproxil Hydroxychloroquine Placebo |
Plan Nacional sobre el Sida (PNS) | This study aims to assess the efficacy of a daily single dose of tenofovir disoproxil fumarate (TDF), a daily single dose of hydroxychloroquine (HC), a daily single dose of TDF plus HC versus placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical severity COVID-19 | Start Date: April 1, 2020 |
Phase 2 |
Hydroxychloroquine Sulfate + Azithromycin | Rutgers, The State University of New Jersey | This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin in order to determine which regimen is more effective. | Start Date: April 6, 2020 |
Phase 4 |
Hydroxychloroquine | Instituto de Investigación Marqués de Valdecilla | The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or Jak inhibitors. | Start Date: April 6, 2020 |
Phase 3 |
Hydroxychloroquine Sulfate | Tan Tock Seng Hospital | This cluster randomized trial will evaluate the safety and efficacy of oral HCQ PEP, taken over for 5 days, in reducing the number of infected household contacts of confirmed COVID-19 patients under home quarantine. | Start Date: April 2020 |
Phase 3 |
Hydroxychloroquine + azithromycin | Hospital Israelita Albert Einstein | The present study will evaluate the effectiveness and safety of the use of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with pneumonia by SARS-CoV2 virus. | Start Date: March 28, 2020 |
Phase 3 |
Hydroxychloroquine + azithromycin | Hospital do Coracao | Study aims to compared standard of care, hydroxychloroquine plus azythromycin and hydroxychloroquine monotherapy for treatment of hospitalized patients with COVID-19. | Start Date: April 6, 2020 |
Phase 2,3 |
Sarilumab Azithromycin Hydroxychloroquine |
Assistance Publique - Hôpitaux de Paris | The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019 (COVID-19). | Start Date: April 2020 |
Test and Treat COVID 65plus+ (COVID65plus) Phase 2,3 |
Hydroxychloroquine | University Hospital Tuebingen | Patients over equal or older than 65 years will be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. | Start Date: May 1, 2020 |
Phase 2,3 |
Hydroxychloroquine Remdesivir Standard of Care |
Oslo University Hospital | The WHO NOR- COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. | Start Date: March 26, 2020 |
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment Phase 2,3 |
Chloroquine Nitazoxanide Ivermectin |
Tanta University | Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment | Start Date: April 17, 2020 |
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol (FMTVDM) Phase 2,3 |
Hydroxychloroquine Azithromycin Doxycycline Clindamycin Primaquine Remdesivir Tocilizumab Methylprednisolone Interferon-Alpha2B Losartan Convalescent Serum |
The Camelot Foundation | The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives. | Start Date: April 11, 2020 |
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) Phase 2 |
Hydroxychloroquine Sulfate | University of Pennsylvania | This study evaluates the safety and efficacy of hydroxychloroquine in the treatment of COVID-19. | Start Date: April then 8, 2020 |
Phase 2 |
Clevudine Hydroxychloroquine |
Bukwang Pharmaceutical | The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg once a day for 14 days (maximum up to 21 days) and of Hydroxychloroquine 200mg twice a day for 14 days (maximum up to 21 days) of administration in patients with moderate COVID-19. | Start Date: April 24, 2020 |
The Vietnam Chloroquine Treatment on COVID-19 (VICO) Phase 2 |
Chloroquine Phosphate | Oxford University Clinical Research Unit, Vietnam | The purpose of the pilot is to develop the study procedures for the randomized controlled trial, including the safe monitoring of patients, to refine the CRF, and to acquire some preliminary data on the safety of chloroquine in those with COVID-19. | Start Date: April 1, 2020 |
Phase 3 |
Hydroxychloroquine Azithromycin |
LCMC Health | This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. | Start Date: April 10, 2020 |
Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic Phase 3 |
Antiviral treatment (Chloroquine, Darunavir/Cobicstat) and prophylaxis | Oriol Mitja, Germans Trias i Pujol Hospital | The investigators plan to evaluate the efficacy of the 'test and treat' strategy of infected patients and prophylactic chloroquine treatment to all contacts. The strategy entails decentralized COVID-19 testing and starting antiviral darunavir/cobicistat plus chloroquine treatment immediately in all who are found to be infected. | Start Date: March 15, 2020 |
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients Phase 2 |
Liponavir/Ritonavir hydroxychloroquine sulfate baricitinib sarilumab |
Nova Scotia Health Authority Halifax, Nova Scotia, Canada |
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment | Start Date: April 2020 |
Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy) Phase 3 |
Remdesivir Lopinavir/ritonavir Interferon Beta-1A Hydroxychloroquine Standard of care |
Institut National de la Santé Et de la Recherche Médicale, France |
The primary objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19. | Start Date: March 22, 2020 |
Umifenovir in COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial (UAIIC) Phase 4 |
Umifenovir Interferon-β 1a Lopinavir / Ritonavir Single Dose of Hydroxychloroquine Standards of Care |
Shahid Beheshti University of Medical Sciences | The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. | Start Date: April 15, 2020 |
University of Utah COVID-19 Hydrochloroquine Trial Phase 2 |
Hydroxychloroquine | University of Utah | The rationale for this clinical trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19. | Start Date: April 14, 2020 |
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) Phase 3 |
Hydroxychloroquine Sulfate Hydroxychloroquine Sulfate + Azythromycin |
Apsen Farmacêutica S.A. São Paulo, Brazil |
Hydroxychloroquine is a drug with great potential treatment, as it can inhibit the pH-dependent steps of replication of various viruses, with a potent effect on SARS-CoV infection and spread. In this way, the present study will evaluate the safety and efficacy of the hydroxychloroquine in patients with symptomatic SARS-Cov2. | Start Date: May 4, 2020 |
Phase 3 |
Oseltamivir Chloroquine Lopinavir Ritonavir Favipiravir Oseltamivir Darunavir |
Thailand, Rajavithi Hospital | A 6-Week Prospective, Open label, Randomized, in Multicenter Study evaluating the efficacy and safety of various combinations of protease inhibitors in the treatment of COVID-19. | Start Date: March 15, 2020 |
Will Hydroxychloroquine Impede or Prevent COVID-19 (WHIP COVID-19) Phase 3 |
Hydroxychloroquine | Henry Ford Health System | The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection. | Start Date: April 7, 2020 |
Publications
Title | Authors | Journal | Date | Summary |
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19 | Meo SA, Klonoff DC, Akram J. | European Review for Medical and Pharmacological Sciences | April 24, 2020 | A review of the treatment of chloroquine and hyroxychloroquine for COVID-19 infections. The results suggest that these drugs have efficacy for treating COVID-19. |
Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19 | Ruamviboonsuk P., Lai TYY., Chang A., Lai CC., Mieler WF., Lam DSC. | The Asia-Pacific Journal of Ophthalmology | Mar-Apr 2020 | Discusses the potential of chloroquine to cause retinal damage when used in high doses over a short period of time for COVID-19 treatment. |
Convalescent Plasma
Treatment Description
Antibody rich plasma provided by COVID-19 convalescent patients (Tiberghien et al 2020) and given to patients infected with SARS-CoV-2 |
Has been used previously for 1918 pandemic flu, measels, MERS-CoV, SARS, and Ebola (Rubin R., 2020) |
US Food and Drug Administration will facilitate access to convalescent plasma for the treatment of COVID-19 (Rubin R. 2020) |
Clinical Trials
Name of Study | Intervention | Location | Description | Progress |
Phase 2 |
Convalescent Plasma | Max Super Speciality hospital, Saket New Delhi, Delhi, India |
We designed this phase II, open label, randomized clinical trial with the primary objective to assess the safety and efficacy of the therapy in the second stage. | Start Date: May 9, 2020 |
Phase 2 |
anti-SARS-CoV-2 convalescent plasma | Froedtert Hospital Milwaukee, Wisconsin, United States |
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19. | Start Date: May 11, 2020 |
Anti COVID-19 Convalescent Plasma Therapy Early Phase 1 |
anti-SARS-CoV-2 convalescent plasma | Orthosera Kft. | Our hypothesis is that convalescent plasma transfusion from healthy donors who recovered from SARS CoV-2 is able to reduce the cytokine storm in addition to replenish the patient's own antibodies in the acutely infected phase of the disease. | Start Date: April 14, 2020 |
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 | Convalescent Plasma | Shanghai Public Health Clinical Center | The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia. | Start Date: February 1, 2020 |
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program | Convalescent Plasma | This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma. | ||
Phase 1,2 |
Hyperimmune plasma Hidroxicloroquina + Azitromicina Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina |
Hospital Unversitario Virgen Macarena Sevilla, Spain |
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection. | Start Date: April 2020 |
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients | Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients | RFMN - Clinical Research Center for Rare Diseases Ranica, BG, Italy ASST HPG23 - Unit of Nephrology Bergamo, Italy ASST Papa Giovanni XXIII - Microbiology and Virology Unit Bergamo, Italy Asst Pg23 - S.I.M.T Bergamo, Italy ASST-PG23 - Intensive Care Unit Bergamo, Italy |
A pilot study aimed to explore whether the infusion of antibodies obtained with one single DFPP procedure from voluntary convalescent donors could offer an effective and safe therapeutic option for critically ill patients with severe coronavirus (COVID-19) pneumonia requiring mechanical ventilation. | Start Date: April 15, 2020 |
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia | Convalescent SARS COVID-19 plasma Placebo |
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of clinical status at day 30 after study initiation. | Start Date: May 15, 2020 | |
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection Phase 2 |
Convalescent Plasma | Hackensack Meridian Health | This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. | Start Date: April 9, 2020 |
Convalescent Plasma Collection and Treatment in Pediatrics and Adults Phase 3 |
Convalescent Plasma | WVU Medicine Morgantown, West Virginia, United States |
This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement | Start Day: April 16, 2020 |
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia Phase 2 |
Plasma | Hospital Universitario José E. Gonzalez Monterrey, Nuevo Leon, Mexico |
Randomized clinical trial comparing convalescent plasma to best available therapy (BAT) for the treatment of severely ill and critically ill patient with COVID-19. | Start Date: April 27, 2020 |
Convalescent Plasma for COVID-19 | Blood plasma | The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 | Start Date: April 27, 2020 | |
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) (CONCOR-1) Phase 3 |
Convalescent plasma | McMaster University (Hamilton Health Sciences Corporation) | The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. | Start Date: April 27, 2020 |
Convalescent Plasma for Ill Patients by COVID-19 Phase 1,2 |
Convalescent Plasma | Hospital Del Issste Regional En Guadalajara Jalisco Guadalajara, Jalisco, Mexico Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado Hermosillo, Sonora, Mexico Hospital Central Norte Pemex Mexico City, Mexico hospital general de Mexico Mexico City, Mexico |
The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients. | Start Date: May 2020 |
Convalescent Plasma for Patients With COVID-19 Phase 2 |
Convalescent Plasma | Henry Ford Hospital Detroit, Michigan, United States |
Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease. | Start Date: May 4, 2020 |
Convalescent Plasma for Patients With COVID-19: A Pilot Study (CP-COVID-19) Phase 2 |
Plasma | Universidad del Rosario | The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). | Start Date: April 1, 2020 |
Phase 2,3 |
Plasma, Hydroxychloroquine, Azithromycin | Universidad del Rosario | The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). | Start Date: April 1, 2020 |
Convalescent Plasma for the Treatment of Patients With COVID-19
|
COVID-19 Convalescent Plasma | Multiple sites in Colorado, United States | The primary objective of this expanded access program is to provide COVID-19 convalescent plasma to patients with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such manifestations. | |
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Phase 2 |
Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma | University of Virginia Medical Center Charlottesville, Virginia, United States University of Virginia Charlottesville, Virginia, United States |
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will be enrolled to receive anti-SARS-CoV-2 plasma. | Start Date: May 5, 2020 |
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study Phase 1,2 |
SARS-CoV-2 convalescent plasma | Danderyd Hospital Danderyd, Stockholm, Sweden Karolinska University Hospital Stockholm, Sweden |
The proposed study thus aims to treat a high risk population identified by having viremia irrespective of but hopefully before they develop pulmonary injury such that they require supplementary oxygen therapy. | Start Date: May 7, 2020 |
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure Early Phase 1 |
Multiple Doses of Anti-SARS-CoV-2 convalescent plasma | 8700 Beverly Blvd. Los Angeles, California, United States Johns Hopkins University Baltimore, Maryland, United States University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States | This study will assess the feasibility of administering multiple doses of convalescent plasma (from people who have recovered form SARS-CoV-2) to Covid-19 positive patients in the Intensive Care Unit receiving mechanical ventilation. | Start Date: May 2020 |
Convalescent Plasma in the Treatment of COVID 19 Phase 2 |
Convalescent Plasma | Saint Francis Care | The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection. | Start Date: April 10, 2020 |
Phase 2,3 |
Convalescent Plasma | Bart Rijnders, Erasmus Medical Center | With no proven effective therapy against COVID-19, this protocol will evaluate the therapeutic potential of therapy with convalescent plasma from COVID-19 recovered donors. | Start Date: April 1, 2020 |
Phase 2 |
Blood and derivatives, Standard of Care | Puerta de Hierro University Hospital | A multi-center, randomized, clinical trial with two arms to study the efficacy and safety of passive immunotherapy with CP compared to a control of standard of care (SOC). | Start Date: April 3, 2020 |
Convalescent Plasma to Limit Coronavirus Associated Complications Phase 2 |
Convalescent Plasma | Mayo Clinic | Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19. | Start Date: April 1, 2020 |
Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients Phase 2 |
Convalescent Plasma | Montefiore Medical Center Bronx, New York, United States NYU Langone Health New York, New York, United States |
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation. | Start Date: April 17, 2020 |
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004)
Phase 2
|
SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor | To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding. | Start Date: May 11, 2020 | |
Convalescent Plasma Trial in COVID -19 Patients | convalescent plasma with antibody against SARS-CoV-2 | Royal College of Surgeons in Ireland - Bahrain Manama, Bahrain |
The objective of this pilot study is to compare plasma therapy using convalescent plasma with antibody against SARS-CoV-2 to usual supportive therapy in COVID-19 patients with pneumonia and hypoxia, and to determine if the clinical course is improved. | Start Date: April 19, 2020 |
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Phase 3 |
Plasma from COVID-19 convalescent patient Human immunoglobulin |
Centenario Hospital Miguel Hidalgo Aguascalientes, Mexico |
Objective: To assess the safety and efficacy of the administration of Convalescent plasma vs human immunoglobulin in critically ill patients with COVID-19 infection. | Start Date: May 6, 2020 |
Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19 Phase 2 |
Convalescent Plasma | Stanford University Stanford, California, United States |
This study will evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma (convalescent plasma) versus control (standard plasma) in patients with COVID-19 respiratory symptoms. | Start Date: May 2020 |
Convalescent Plasma vs. Standard Plasma for COVID-19 Phase 1,2 |
Convalescent Plasma, Standard Donor Plasma | Stony Brook University | The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. | Start Date: April 8, 2020 |
COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma Phase 2 |
Convalescent Plasma | Centro de Hematología y Medicina Interna Puebla, Mexico |
Injecting convalescent plasma into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies. | Start Date: April 13, 2020 |
COVID-19 Convalescent Plasma |
anti-SARS-CoV-2 convalescent plasma | University of Chicago | The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19. | Start Date: April 30, 2020 |
COVID-19 Plasma Collection | Plasma Donation | Thomas Jefferson University | The purpose of this study is to describe the process for identifying and collecting convalescent plasma from donors previously infected with the virus. | Start Date: April 13, 2020 |
CoVID-19 Plasma in Treatment of COVID-19 Patients Early Phase 1 |
Convalescent COVID-19 Plasma | The Christ Hospital Cincinnati, Ohio, United States |
The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in patients requiring hospitalization for symptomatic "high risk" COVID19 disease as reflected by the presence of elevated hsTPN. | Start Date: April 2020 |
Phase 2,3 |
Convalescent Plasma | Fundacion Arturo Lopez Perez Providencia, Santiago, Chile |
This is a collaborative, 4 arms , non randomized clinical trial assessing the use of Convalescent Plasma from COVID-19 recovered donors to be used in oncological and non-oncological patients with current severe COVID-19 infection or in patients with risk factors of major complications secondary to COVID-19 infection | Start Date: April 7, 2020 |
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. (LIFESAVER)
Phase 2,3
|
COVID-19 Convalescent Plasma | Fondazione Policlinico Universitario A. Gemelli IRCCS Roma, RM, Italy Ospedale SS Annunziata Chieti, Italy Istituto Nazionale Malattie Infettive Lazzaro Spallanzani Rome, Italy |
The investigators hypothesize that transfusing convalescent plasma (containing neutralizing antibodies) at an early phase of COVID-19 infection could prevent or switch off the persistent inflammatory response elicited by the virus. | Start Date: May 15, 2020 |
Phase 2,3 |
Convalescent Plasma | Dr. Cipto Mangunkusumo General Hospital Jakarta, DKI Jakarta, Indonesia St. Carolus Hospital Jakarta, DKI Jakarta, Indonesia PELNI Hospital Jakarta, DKI Jakarta, Indonesia |
The use of convalescent plasma has been approved by the US Food and Drug Administration (FDA) through the scheme of emergency investigational new drug (eIND). This method has been used as the treatment in several outbreak or plague cases over the years, such as the flu epidemic in 1918, polio, measles, mumps, SARS (severe acute respiratory syndrome), EVD (Ebola virus disease) and MERS (middle-eastern respiratory syndrome) and this treatment shows better outcome. | Start Date: May 11, 2020 |
Phase 2 |
Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma | Johns Hopkins University | Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28. | Start Date: May 1, 2020 |
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
Phase 2 |
COVID-19 convalescent plasma | Hospital Clínico Universidad Católica Santiago, Chile |
This study is an open-label randomized trial in which patients with high risk of COVID19-associated respiratory failure will be randomized to early treatment with convalescent plasma (< 7 days from symptoms start) or at early signs of respiratory failure or prolonged hospitalization. COVID-19 convalescent plasma will be collected from individuals according to the institutional protocol. | Start Date: May 4, 2020 |
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Phase 3 |
Convalescent anti-SARS-CoV-2 plasma Sarilumab Baricitinib Hydroxychloroquine Placebo |
Various Locations in Denmark | CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled, multi-stage trial, which aims to assess the safety and efficacy of novel treatment option of moderate-severe COVID-19. | Start Date: April 20, 2020 |
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients Phase 2 |
Convalescent Plasma Transfusion | Institute of Liver and Biliary Sciences, India Maulana Azad medical College New Delhi, Delhi, India |
We have planned a randomized controlled trial to assess the efficacy of convalescent plasma from recovered COVID-19 infected patients in COVID-19 infected sick patients. | Start Date: April 14, 2020 |
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (PLASCOSSA)
Phase 3
|
Transfusion of SARS-CoV-2 Convalescent Plasma | HIA Percy Clamart, France HIA Laveran Marseille, France HIA Bégin Saint-Mandé, France HIA Sainte Anne Toulon, France |
PlasCoSSA is a randomized, controlled, triple-blinded, parallel clinical trial. This study tests the efficacy of convalescent plasma transfusion therapy in the early care of COVID-19 hospitalized patients outside intensive care units. | Start Date: May 2020 |
Phase 2 |
Transfusion of COVID-19 convalescent plasma | Hôpitaux de Paris | The objective of COVIPLASM trial (a nested trial in the CORIMUNO-19 COHORT) is to study the efficacy of convalescent plasma to treat SARS-COV2 infected patients. | Start Date: April 14, 2020 |
Phase 2 |
Convalescent Plasma | Various Children's Hospitals in Canada | This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment for COVID-19 disease in hospitalized children in the context of the COVID-19 pandemic. | Start Date: May 1, 2020 |
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy | High-Titer COVID-19 Convalescent Plasma (HT-CCP) Standard Plasma (FFP) |
In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS. | Start Date: April 2020 | |
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | COVID-19 Convalescent Plasma | Mayo Clinic (Various Locations around the US) | This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. | Start Date: April 2020 |
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 | COVID-19 convalescent plasma | Tulane Medical Center New Orleans, Louisiana, United States |
This is a single-arm feasibility study to assess the safety and efficacy of anti-SARS-CoV-2 convalescent plasma (CP) in intubated, mechanically ventilated patients with confirmed COVID-19 pneumonia by chest X-ray or chest CT. hospitalized patients with acute respiratory symptoms between 3 and 7 days after the onset of symptoms, with COVID-19. |
|
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) Phase 1 |
Anti-SARS-CoV-2 Human Convalescent Plasma | The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent exposure. | Start Date: May 18, 2020 | |
Hyperimmune Plasma for Critical Patients With COVID-19 (COV19-PLASMA) | hyperimmune plasma | Foundation IRCCS San Matteo Hospital | We plan to treat critical Covid-19 patients with hyperimmune plasma. | Start Date: March 17, 2020 |
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19 Phase 2 |
Inactivated convalescent plasma | Multiple sites in Columbia | This study consists of obtaining convalescent plasma by means of apheresis, from recovered donors, who meet the eligibility criteria to donate. | Start Date: May 20, 2020 |
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial | Convalescent Plasma | Mazandaran University of Medical Sciences | In this study the investigators aim to determine the effect of Convalescent Plasma on COVID-19 patients Outcome through a Clinical Trial. | Start Date: March 28, 2020 |
Passive Immunity Trial of Nashville II for COVID-19 Phase 3 |
pathogen reduced SARS-CoV-2 convalescent plasma | Vanderbilt University Medical Center Nashville, Tennessee, United States |
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. | Start Date: April 24, 2020 |
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial (REP-COVID)
Phase 2
|
Plasma exchange | Hospital Clinic i Provincial de Barcelona Barcelona, Spain, |
Plasma exchanges with 5% human albumin (2/3 of the exchanged plasma volume) and fresh frozen plasma (FFP: 1/3) in patients with quick <50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit. | Start Date: April 29, 2020 |
Plasma Rich Antibodies From Recovered Patients From COVID19 (PRA-001) | Antibody-Rich Plasma from COVID-19 recovered patients | Ain Shams University | Prospective interventional study, single arm of purified convalescent plasma transfusion as an add on therapy for the standard of care treatment (national guideline), Oseltamivir, and hydroxychroquine ± Azithromycin daily for 5 days | Start Date: April 20, 2020 |
Plasma Therapy of COVID-19 in Critically Ill Patients Phase 2 |
Convalescent Plasma (anti-SARS-CoV-2 plasma) Non-convalescent Plasma (control plasma) |
Columbia University Irving Medical Center/NYP New York, New York, United States |
This randomized blinded phase 2 trial will assess the efficacy and safety of Anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. | Start Date: April 21, 2020 |
Phase 2 |
convalescent plasma from recovered COVID 19 donor | King Fahad Specialist Hospital Dammam | We are proposing to test the therapeutic potential of convalescent plasma (from patients who have fully recovered from COVID-19) in treating patients with serious COVID-19 disease or those who are at risk of developing a serious disease based on their comorbidities profile. | Start Date: April 12, 2020 |
Safety in Convalescent Plasma Transfusion to COVID-19 Phase 1 |
Convalescent Plasma | Hospital San Jose Tec de Monterrey | The investigator will evaluate the safety and efficacy of plasma obtained from convalescent individuals with proven novel SARS-CoV-2 virus infection, diagnosed with coronavirus-19-induced disease and symptom-free for a period of not less than 10 days in the treatment of individuals infected with COVID-19. | Start Date: April 15, 2020 |
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) | SARSCoV2 Convalescent Plasma | AdventHealth Orlando Orlando, Florida, United States |
The purpose of this trial is to provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19. | |
Study Testing Convalescent Plasma vs Best Supportive Care Phase 1 |
high-titer anti-Sars-CoV-2 plasma | Baylor Research Institute | The study aims to evaluate the efficacy of convalescent plasma in the treatment of COVID-19. | Start Date: April 1, 2020 |
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | Anti-Sars-CoV-2 Convalescent Plasma | This treatment protocol is designed to provide a treatment option for patients diagnosed with severe or life-threatening COVID-19 or judged by the subinvestigator (treating physician) to be at high risk of progressing to severe or life threatening disease |
Publications
Title | Authors | Journal | Date | PID | Summary |
Convalescent Plasma in Covid-19: Possible Mechanisms of Action | Rojas M., Rodriguez Y., et al. | Autoimmunity Reviews | May 5, 2020 | 32380316 | This article discusses the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system and immunomodulation of a hypercoagulable state. |
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Zhang B., et al. | Chest | March 31, 2020 | 32243945 | Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. |
Deployment of Convalescent Plasma for the Prevention and Treatment of COVID-19 | Bloch E. M., et al. | Journal of Clinical Investigation | April 7, 2020 | 32254064 | We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. |
Use of Convalescent Plasma Therapy in Two COVID-19 Patients With Acute Respiratory Distress Syndrome in Korea | Ahn J. Y., Sohn Y., Lee S. H., et al. | Journal of Korean Medical Science | April 13, 2020 | 32281317 | We describe two cases of COVID-19 treated with convalescent plasma infusion. Both patients presented severe pneumonia with acute respiratory distress syndrome and showed a favorable outcome after the use of convalescent plasma in addition to systemic corticosteroid. To our knowledge, this is the first report of the use of convalescent plasma therapy for COVID-19 in Korea. |
Treatment With Convalescent Plasma for COVID-19 Patients in Wuhan, China | Ye M., Fu D., Ren Y., et al. | Journal of Medical Virology | April 15, 2020 | 32293713 | In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. |
Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients | Duan K., Liu B., Li C., et al. | Proceedings of the National Academy of Sciences of the United States of America | April 28, 2020 | 32253318 | In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. |
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients | Zeng Q. L., Yu Z. J., Gou J. J., et al. | The Journal of Infectious Diseases | April 29, 2020 | 32348485 | In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier. |
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | Shen C., Wang Z., Zhao F., et al. | The Journal of the American Medical Association | March 27, 2020 | 32219428 | In this uncontrolled case series of 5 critically ill patients with COVID-19 and acute respiratory distress syndrome (ARDS), administration of convalescent plasma containing neutralizing antibody was followed by an improvement in clinical status. |
Collecting and Evaluating Convalescent Plasma for COVID-19 Treatment: Why and How? | Tiberghien P., Laballerie X., Morel P., Gallian P., Lacombe K., Yazdanpanah Y. | Vox Sanguinis | April 2, 2020 | 32240545 | Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. |
Favipiravir
Drug Description
Broad spectrum inhibitor of viral RNA polymerase (Furata et al 2020) |
Discovered for the use against influenza virus |
RNA-dependent RNA polymerase (RdRp) is conserved among vairus types of RNA viruses (Furata et al 2020) |
Clinical Trials
Name of Study | Intervention | Location | Description | Progress |
Phase 3 |
Favipiravir Hydroxychloroquine Azithromycin Zinc Sulfate Standard of care management |
Chelsea and Westminster Hospital West Middlesex University Hospital |
A prospective, randomised, open label study of the combined use of azithromcycin, hydroxychloroquine, zinc and standard clinical care verses favipiravir and standard clinical care verses standard clinical care alone. | Start Date: May 1, 2020 |
A Real-life Experience on Treatment of Patients With COVID 19 Phase 2,3 |
Chloroquine Favipiravir Nitazoxanide Ivermectin Niclosamide |
Tanta University | COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin. | April 15, 2020 |
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 Phase 3 |
Favipiravir Placebo |
Asst Fatebenefratelli Sacco Milano, Italy, 20157 |
This study evaluates treatment with Favipiravir combined with supportive care for adult patients with COVID-19-moderate type. | Start Date: March 25, 2020 |
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive | Favipiravir | Multiple Locations in China | To investigate the mechanism, clinical outcome and therapeutic efficacy with favipiravir of Corona Virus Disease 2019 patients whose nucleic acids changed from negative to positive. | Start Date: April 1, 2020 |
Efficacy and Safety of Favipiravir in Management of COVID-19 (FAV-001) Phase 3 |
Favipiravir Standard of Care |
Ain Shams University | Randomized controlled interventional trial (Clinical Trial) phase 3 to assess the safety and efficacy of favipiravir versus the standard care therapy in the treatment of patients with COVID-19. | Start Date: April 20, 2020 |
Efficacy of Faviprevir in COVID-19 Treatment Phase 2,3 |
Favipiravir Placebo |
Tanta University Tanta, Egypt |
Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 treatment | Start Date: April 17, 2020 |
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19 |
Bromhexine Hydrochloride Tablets Arbidol Hydrochloride Granules Recombinant Human Interferon α2b Spray Favipiravir |
China, Zhejiang The Second AffIliated Hospital of Wenzhou Medical University |
Compare the efficacy and safety of Bromhexine Hydrochloride Tablets combined with standard treatment/ standard treatment in patients with suspected and mild, or common novel coronavirus pneumonia (COVID-19). | Start Date: February 16, 2020 |
Favipiravir Combined With Tocilizumab in the Treatment of Coronavirus Disease 2019 |
Favipiravir Combined With Tocilizumab Favipiravir Tocilizumab |
Gilead Sciences (Stanford (CA), Newport Beach (CA), Seattle (WA), Everett (WA), Hong Kong, South Korea, Singapore, Taiwan) | The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of coronavirus disease 2019. | Start Date: March 8, 2020 |
Favipiravir in Hospitalized COVID-19 Patients (FIC)
Phase 4
|
Favipiravir Hydroxychloroquine |
Shahid Modarres Hospital Shahid Beheshti University of Medical Sciences and Health Services Tehran, Iran, Islamic Republic of |
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. | Start Date: April 20, 2020 |
Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19 Phase 2 |
Favipiravir | Stanford University | The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease. | Start Date: April 2020 |
Safety and Efficacy of Hydroxychloroquine + Favipiravir Drug Regimen in Comparison With Hydroxychloroquine + Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19 |
Favipiravir Hydroxychloroquine Kaletra |
Start Date: March 29, 2020 | ||
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 Phase 2 |
Favipiravir + Standard of Care
|
Brigham and Women's Hospital Massachusetts General Hospital UMass Memorial Health Care |
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance. | Start Date: April 17, 2020 |
Phase 3 |
Hydroxychloroquine Imatinib Favipiravir Telmisartan |
Bordeaux university Hospital Bordeaux, France |
This trial will estimate the efficacy and tolerance of several experimental treatments to prevent hospitalization or death in outpatients aged 65 years or above with Symptomatic SARS-CoV-2 Infection (COVID-19). | Start Date: April 15, 2020 |
Publications
Title | Authors | Journal | Date | Summary |
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study | Cai Q., Yang M., et al. | Engineering (Beijing) | March 18, 2020 | Examine efficacy of Favipiravir vs. Lopinavir/Ritonavir for the treatment of COVID-19. Favipiravir showed better results for disease progression and viral clearance. |
Other
Drug/Treatment Descriptions
Meplazumab
Humanized IgG2 monoclonal antibody against CD147 |
Inhibits SARS_CoV-2 replication and virus-inducced cytopathic effect in Vero E6 cells (Bian et al 2020) |
Arbidol
ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate |
Broad -specturm antiviral with demonstrated activity against both enveloped and non-enveloped viruses (Boriskin et al 2008) |
Darunavir/Cobicistat
Hasn't been proven effective |
HIV protease inhibitor (Kakuda et al 2015) |
mRNA-1273
Manufactured by ModernaTX, Inc. |
A novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine (Wang et al 2020) |
Encodes for a full length prefusion stabilized spike (S) protein of 2019 novel coronavirus (Wang et al 2020) |
Clinical Trials
Name of Study | Intervention | Location | Description | Progress |
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia Phase 1,2 |
Meplazumab for Injection | Shaanxi Tangdu Hospital Xi'an, Shaanxi, China | According to the results of nonclinical study of humanized Meplazumab for Injection, a single dose will be used for the treatment. Each subject will be evaluated the therapeutic effect within 28 days after the first administration, and to determine the preliminary therapeutic effect, safety and tolerability of humanized Meplazumab for Injection. | Start Date: February 3, 2020 |
Phase 4 |
Arbidol Hydrochloride | No Locations Provided | 380 eligible patients with pneumonia diagnosed with 2019-ncov infection were randomly assigned to one of two treatment groups at a 1:1 ratio. Patients will receive one of two treatment regimens: A .Abidor tablets + basic treatment B. basic treatment Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days Basic treatment :The basic treatment used by the investigator was based on the condition of the patient. | Start Date: February 7, 2020 |
Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV Phase 3 |
Darunavir, Cobicistat | Shanghai Public Health Clinical Center Shanghai, China | There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of pneumonia caused by the 2019 novel coronavirus | Start Date: January 30, 2020 |
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection Phase 1 |
mRNA-1273 | Emory Children's Center - Pediatric Infectious Diseases Decatur, Georgia, United States Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases Seattle, Washington, United States | This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of 2019-novel coronavirus (nCoV). | Start Date: March 3, 2020 |
Publications
Arbidol
Title | Authors | Journal | Date | Summary |
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ? | Vankadari N. | International Journal of Antimicrobial Agents | April 28, 2020 | This article shows the target and mechnism of action for Arbidol. It provides the structural and molecular dynamics for how Aribidol can target SARS-CoV-2. |
Tocilizumab
Title | Authors | Journal | Date | PID | Summary |
Off-label Use of Tocilizumab for the Treatment of SARS-CoV-2 Pneumonia in Milan, Italy
|
Morena, et al. | European Journal of Internal Medicine | May 21, 2020 | 32448770 | In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. |
Tocilizumab for the Treatment of Severe Coronavirus Disease 2019
|
Alattar R., et al. | Journal of Medical Virology | May 5, 2020 | 32369191 | This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. |
Tocilizumab Treatment in COVID-19: A Single Center Experience
|
Luo P., Liu Y., Qiu L., Liu X., Liu D., Li J. | Journal of Medical Virology | April 6, 2020 | 32253759 | In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients. |
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. | Klopfenstein, T. et al. | Med Mal Infect. | May 6, 2020 | 32387320 | Tocilizumab may reduce ICU admission and mortality of SARS-CoV-2 pneumonia cases. |
Effective Treatment of Severe COVID-19 Patients With Tocilizumab
|
Xu X., et al. | Proceedings of the National Academy of Sciences of the United States of America | May 19, 2020 | 32350134 | This study aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. |
Additional COVID-19 Related Resources
Please check the following for more information on ongoing/prospective clinical trials regarding COVID-19 and other COVID-19-related resources.
- Center for Disease Control and Prevention (CDC) Coronavirus Resources
- ClinicalTrials.gov
- Harvard Health - Coronavirus Resource Center
- Johns Hopkins Coronavirus Resource Center
- National Institute of Health (NIH) Coronavirus Health Information
- UCSF Novel Coronavirus Resources
- US Department of Labor Coronavirus Resources
This page is sponsored by Dr. Timothy Henrich and the Henrich Lab.
For additional questions please contact Tim at [email protected].
If you are interested in providing additional resources please contact Joanna at [email protected].